News
SEEL
0.4400
-6.60%
-0.0311
Weekly Report: what happened at SEEL last week (0715-0719)?
Weekly Report · 4d ago
'MDMA Therapy Gets Support From Prominent Research Group As FDA Weighs Action' - Green Market Report
23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD. More than 17 U.S. Military veterans commit suicide each day due to PTSD. The paper noted that MDMA therapies have been proven safe and effective by multiple studies. The FDA is slated to rule on a new drug application for MDMA therapy by Aug. 11.
Benzinga · 07/16 18:51
Weekly Report: what happened at SEEL last week (0708-0712)?
Weekly Report · 07/15 12:10
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
SeaStar Medical Holding Corporation shares fell 34% to $8.55 on Wednesday. Virpax Pharmaceuticals, Inc. Shares jumped 139% in the mid-day session. The company entered into a $10 million registered direct offering of shares at $10.55 per share.
Benzinga · 07/10 17:18
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Ampco-Pittsburgh stock is rocketing more than 75% on commercial contract wins and backlog news. Vivopower shares are soaring over 54% on a new extended loan facility agreement. Seelos Therapeutics stock is surging more than 33% in pre-market trading. Biggest pre- market stock movers are new contracts and agreements.
Investorplace · 07/10 11:23
Why VivoPower International Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Shares of VivoPower International PLC rose sharply in today's pre-market trading. The company announced it secured an extension for a $34 million loan financing facility agreement. Ampco-Pittsburgh Corporation shares rose 72.6% to $1.32 in pre- market trading.
Benzinga · 07/10 09:34
Weekly Report: what happened at SEEL last week (0701-0705)?
Weekly Report · 07/08 12:13
Weekly Report: what happened at SEEL last week (0624-0628)?
Weekly Report · 07/01 12:13
Weekly Report: what happened at SEEL last week (0617-0621)?
Weekly Report · 06/24 12:24
Weekly Report: what happened at SEEL last week (0610-0614)?
Weekly Report · 06/17 12:12
Seelos Therapeutics files to sell 924K shares of common stock for holders
Seeking Alpha · 06/14 20:20
'Oregon's First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching' - Marijuana Moment
Oregon's first regulated psilocybin mushroom market in the world is short on customers. Advocates say the industry needs to get the word out about its benefits. One service center in Oregon has closed down for a lack of customers. To date, roughly 3,500 clients have taken a supervised trip in Oregon's 25 licensed mushroom centers. "Unfortunately we've seen one service center close down. It's going to get oversaturated"
Benzinga · 06/12 18:07
Weekly Report: what happened at SEEL last week (0603-0607)?
Weekly Report · 06/10 12:15
12 Health Care Stocks Moving In Friday's Pre-Market Session
Venus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. Geron stock moved upwards by 22.36% during the session. Adlai Nortye and BioCardia were the biggest gainers in the company's Q4 earnings.
Benzinga · 06/07 12:08
Psychedelic stocks fall as FDA panel rejects MDMA therapy
Psychedelic stocks fall as FDA panel rejects MDMA therapy. The selloff comes after a panel of independent advisors to the U.S. FDA declined to endorse marketing authorization for psychiatric therapy. Notable decliners include Mind Medicine, Atai Life Sciences and Cybin.
Seeking Alpha · 06/05 11:17
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
Healthcare FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD. A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
Seeking Alpha · 06/04 21:32
Weekly Report: what happened at SEEL last week (0527-0531)?
Weekly Report · 06/03 12:18
Psychedelic stocks mixed as FDA comments on MDMA therapy
Healthcare Psychedelic stocks mixed as FDA comments on MDMA therapy. If approved, MDMA is set to become the first psychedelic-assisted therapy authorized by the FDA. Leading psychedelic-focused drug developers include GH Research, Mind Medicine, and Cybin. FDA commented on Lykos Therapeutics' marketing application for midomafetamine (MDMA)
Seeking Alpha · 05/31 14:43
Weekly Report: what happened at SEEL last week (0520-0524)?
Weekly Report · 05/27 12:25
Weekly Report: what happened at SEEL last week (0513-0517)?
Weekly Report · 05/20 12:15
More
Webull provides a variety of real-time SEEL stock news. You can receive the latest news about Seelos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.